Literature DB >> 16216151

Nonmedical use and abuse of scheduled medications prescribed for pain, pain-related symptoms, and psychiatric disorders: patterns, user characteristics, and management options.

Meredith Y Smith1, George Woody.   

Abstract

The nonmedical use of scheduled medications commonly prescribed for pain, pain-related symptoms, and psychiatric disorders began rising in the mid-1990s. Physicians are confronted with the dilemma of how to minimize the abuse and diversion potential of these products without compromising access for patients with a legitimate medical need. Using data from the National Survey on Drug Use and Health, we describe the scope of nonmedical use of opioids, stimulants, and tranquilizers; characteristics of nonmedical users; and options available to reduce abuse liability. In 2003, lifetime prevalence estimates of nonmedical use were 31.2 million for opioids, 20.7 million for stimulants, and 20.2 million for tranquilizers. Nonmedical users of psychotherapeutics were more likely to be Caucasian; use alcohol, cocaine, or heroin; and to use needles to inject drugs than those who reported using illicit drugs only. Sources of diversion are enumerated, and options for minimizing the abuse liability associated with these medications are described.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16216151     DOI: 10.1007/s11920-005-0033-4

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  24 in total

1.  Federal reports say oxycodone abuse is on the rise.

Authors:  D Young
Journal:  Am J Health Syst Pharm       Date:  2001-07-01       Impact factor: 2.637

2.  Prevalence of illicit drug use among individuals with chronic pain in the Commonwealth of Kentucky: an evaluation of patterns and trends.

Authors:  Laxmaiah Manchikanti; Bert Fellows; Kim S Damron; Vidyasagar Pampati; Carla D McManus
Journal:  J Ky Med Assoc       Date:  2005-02

3.  Nonmedical use of prescription opioids among U.S. college students: prevalence and correlates from a national survey.

Authors:  Sean Esteban McCabe; Christian J Teter; Carol J Boyd; John R Knight; Henry Wechsler
Journal:  Addict Behav       Date:  2005-05       Impact factor: 3.913

Review 4.  Pain management and prescription monitoring.

Authors:  David E Joranson; Grant M Carrow; Karen M Ryan; Linda Schaefer; Aaron M Gilson; Patricia Good; John Eadie; Susan Peine; June L Dahl
Journal:  J Pain Symptom Manage       Date:  2002-03       Impact factor: 3.612

5.  A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States.

Authors:  T J Cicero; E H Adams; A Geller; J A Inciardi; A Muñoz; S H Schnoll; E C Senay; G E Woody
Journal:  Drug Alcohol Depend       Date:  1999-11-01       Impact factor: 4.492

6.  Illicit use of prescribed stimulant medication among college students.

Authors:  Kristina M Hall; Melissa M Irwin; Krista A Bowman; William Frankenberger; David C Jewett
Journal:  J Am Coll Health       Date:  2005 Jan-Feb

7.  The use of abusable prescription drugs: the role of gender.

Authors:  L Simoni-Wastila
Journal:  J Womens Health Gend Based Med       Date:  2000-04

8.  Benzodiazepine prescription practices and substance abuse in persons with severe mental illness.

Authors:  Robin E Clark; Haiyi Xie; Mary F Brunette
Journal:  J Clin Psychiatry       Date:  2004-02       Impact factor: 4.384

9.  Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents.

Authors:  Robert J Williams; Leslie A Goodale; Michele A Shay-Fiddler; Susan P Gloster; Samuel Y Chang
Journal:  Am J Addict       Date:  2004 Jul-Sep

10.  Patient characteristics and risks factors for development of dependence on hydrocodone and oxycodone.

Authors:  Norman S Miller; Andrea Greenfeld
Journal:  Am J Ther       Date:  2004 Jan-Feb       Impact factor: 2.688

View more
  2 in total

1.  Increasing pregnancy-related use of prescribed opioid analgesics.

Authors:  Richard A Epstein; William V Bobo; Peter R Martin; James A Morrow; Wei Wang; Rameela Chandrasekhar; William O Cooper
Journal:  Ann Epidemiol       Date:  2013-08       Impact factor: 3.797

Review 2.  Molecular genetics of addiction vulnerability.

Authors:  George R Uhl
Journal:  NeuroRx       Date:  2006-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.